Aggressive Lymphomas
From the Journals
Event-free survival at 24 months predicts outcomes in peripheral T-cell lymphomas
Event-free survival at 24 months (EFS24) is predictive of survival in patients with peripheral T-cell lymphomas (PTCLs), according to new findings...
From the Journals
Nivolumab linked to CNS disorder in case report
The disabling neurological symptoms contributed to depressive symptoms that were severe enough for the patient to seek assisted suicide.
News
FDA approves drug to treat rel/ref MCL
The US Food and Drug Administration (FDA) has granted accelerated approval to the BTK inhibitor acalabrutinib (Calquence, formerly ACP-196). The...
News
CCSs more likely to stay at jobs to keep health insurance
Survey results suggest childhood cancer survivors (CCSs) in the US are more likely than individuals without a history of cancer to experience “job...
News
Drug receives breakthrough designation for DLBCL
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to MOR208, an Fc-enhanced monoclonal antibody directed...
News
EMA recommends orphan designation for G100 to treat FL
The European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products has recommended orphan designation for G100 for the treatment of...
From the Journals
Rituximab improves salvage in elderly B-cell lymphoma patients
Rituximab improved the 2-year survival rate from 20.7% to 46.8% for elderly patients with aggressive-B-cell lymphoma who relapsed after CHOP or R-...
News
New assay may aid diagnosis, treatment of DLBCL
A new assay may help improve the diagnosis and treatment of diffuse large B-cell lymphoma (DLBCL), according to researchers. The gene expression...
News
FDA approves second CAR-T therapy
Axicabtagene ciloleucel is the first CAR-T therapy to be approved for use in adults
News
CAR T-cell therapy approved to treat lymphomas
The US Food and Drug Administration (FDA) has approved axicabtagene ciloleucel (Yescarta™, formerly KTE-C19) for use in adults with relapsed or...
News
Natural selection opportunities tied to cancer rates
Countries with the lowest opportunities for natural selection have higher cancer rates than countries with the highest opportunities for natural...